Pliant Therapeutics, Inc. (PLRX) Institutional Ownership

Ownership Summary

Pliant Therapeutics, Inc. (NASDAQ:PLRX) is held by 97 institutional investors per 13F filings through December 2025.

• Their combined ownership stood at 81.4% of outstanding shares in December 2025, down from 86.0% in September 2025.
• Their total shares held in PLRX decreased -3.08% from the prior quarter, while the number of investors in Pliant Therapeutics decreased 38.99% year over year.
• During the quarter, 44 of these 97 funds increased positions in PLRX, 36 reduced exposure, and 17 held steady.
• Institutional investors collectively held 49.99Mn shares in Pliant Therapeutics as of December 2025, down by 1.59Mn shares quarter on quarter, and down 18.17Mn shares year over year.
• TANG CAPITAL MANAGEMENT LLC is the top holder of Pliant Therapeutics as of December 31, 2025, with 6.14Mn shares representing 10.0% of outstanding stock.
• The biggest buyers of Pliant Therapeutics for the quarter ending December 2025 included Blue Owl Capital Holdings LP (2.97Mn), BML Capital Management, LLC (1.55Mn), Prosight Management, LP (1.54Mn), Monaco Asset Management SAM (1.12Mn), Centiva Capital, LP (1.0Mn).
• The largest sales of PLRX for the quarter ending December 2025 came from Point72 Asset Management, L.P. (4.29Mn), Jpmorgan Chase & Co (3.05Mn), Morgan Stanley (2.96Mn), Woodline Partners LP (2.48Mn), Bank Of America Corp /De/ (704.34K).
• According to Business Quant data, leading holders of PLRX for December 2025 are TANG CAPITAL MANAGEMENT LLC (6.14Mn), Blue Owl Capital Holdings LP (5.94Mn), VANGUARD GROUP INC (2.82Mn), CITADEL ADVISORS LLC (2.58Mn), ACADIAN ASSET MANAGEMENT LLC (2.36Mn), Woodline Partners LP (2.03Mn), Monaco Asset Management SAM (1.94Mn), Redmile Group, LLC (1.62Mn), Prosight Management, LP (1.56Mn), BML Capital Management, LLC (1.55Mn).